Alpha Tau Medical

DRTS

Market cap $331M

-  Alpha DaRT pancreatic cancer p atient treatments underway in U.S. multi-center pilot study -

JERUSALEM, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate at the Jefferies Global Healthcare Conference in London on November 18-19, 2025.

-  Receipt of c ritical license marks significant milestone for f irst commercial-scale manufacturing facility for Alpha DaRT ®, the innovative alpha-radiation cancer therapy designed for potent and conformal tumor irradiation -

Alpha DaRT, a unique localized alpha radiation therapy, has shown potential best-in-class efficacy and safety across multiple solid tumors. Currently enrolling patients in cSCC, HNSCC, pancreatic, and GBM (before year end), with a number of milestones across each indication over the next 12-18 months. Despite promising early data and broad potential, Alpha Tau's is currently significantly undervalued at ~$330 million market cap, especially in light of recent acquisitions and trading activity.

– First patient treatment marks successful initiation of multi-center pilot study in Alpha DaRT U.S. pancreatic cancer program –

JERUSALEM, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will present and meet investors in the following five investor conferences in September 2025.

- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer -

- Interim Jan-2025 results from three trials of Alpha DaRT ® in treating pancreatic cancer shared at prestigious 2025 ASCO GI Symposium and R&D Update Day, showing >90% disease control rate , impressive overall survival in sub-group analys e s, and positive safety profile -

JERUSALEM, May 12, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (Nasdaq:  DRTS , DRTSW ) ("Alpha Tau" or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, announced today that Mr. Nadav Kidron, the President, CEO, and Chairman of the Board of Oramed Pharmaceuticals Inc., (“Oramed”), has been appointed to the Company's Board of Directors (“Board”). The appointment follows the recent closing of a strategic investment between the Company and an affiliate of Oramed.

JERUSALEM, May 06, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will presentation in the following investor conferences in May 2025.